Association of VAV2 and VAV3 polymorphisms with cardiovascular risk factors.
Hypertension, diabetes and obesity are cardiovascular risk factors closely associated to the development of renal and cardiovascular target organ damage. VAV2 and VAV3, members of the VAV family proto-oncogenes, are guanosine nucleotide exchange factors for the Rho and Rac GTPase family, which is related with cardiovascular homeostasis. We have analyzed the relationship between the presence of VAV2 rs602990 and VAV3 rs7528153 polymorphisms with cardiovascular risk factors and target organ damage (heart, vessels and kidney) in 411 subjects. Our results show that being carrier of the T allele in VAV2 rs602990 polymorphism is associated with an increased risk of obesity, reduced levels of ankle-brachial index and diastolic blood pressure and reduced retinal artery caliber. In addition, being carrier of T allele is associated with increased risk of target organ damage in males. On the other hand, being carrier of the T allele in VAV3 rs7528153 polymorphism is associated with a decreased susceptibility of developing a pathologic state composed by the presence of hypertension, diabetes, obesity or cardiovascular damage, and with an increased risk of developing altered basal glycaemia. This is the first report showing an association between VAV2 and VAV3 polymorphisms with cardiovascular risk factors and target organ damage.
Translational Research on Renal and Cardiovascular Diseases (TRECARD), Department of Physiology and Pharmacology, University of Salamanca, Salamanca, Spain.|Institute of Health Sciences Studies of Castilla y Leon (IECSCYL), Research Unit, University Hospital of Salamanca, Spain.|Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.
Nuria
N
Perretta-Tejedor
Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.|Molecular Medicine Unit, Department of Medicine, University of Salamanca and Institute of Molecular and Cellular Biology of Cancer (IBMCC), University of Salamanca-CSIC, Salamanca, Spain.
Javier
J
Fernández-Mateos
Translational Research on Renal and Cardiovascular Diseases (TRECARD), Department of Physiology and Pharmacology, University of Salamanca, Salamanca, Spain.|Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.|Research Unit, Primary Care Center of La Alamedilla, Salamanca, Spain.
Luis
L
García-Ortiz
Translational Research on Renal and Cardiovascular Diseases (TRECARD), Department of Physiology and Pharmacology, University of Salamanca, Salamanca, Spain.|Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.|Research Unit, Primary Care Center of La Alamedilla, Salamanca, Spain.
Manuel A
MA
Gómez-Marcos
Translational Research on Renal and Cardiovascular Diseases (TRECARD), Department of Physiology and Pharmacology, University of Salamanca, Salamanca, Spain.|Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.|Research Unit, Primary Care Center of La Alamedilla, Salamanca, Spain.
José I
JI
Recio-Rodríguez
Translational Research on Renal and Cardiovascular Diseases (TRECARD), Department of Physiology and Pharmacology, University of Salamanca, Salamanca, Spain.|Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.|Research Unit, Primary Care Center of La Alamedilla, Salamanca, Spain.
Cristina
C
Agudo-Conde
Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.|Research Unit, Primary Care Center of La Alamedilla, Salamanca, Spain.
Emiliano
E
Rodriguez-Sánchez
Translational Research on Renal and Cardiovascular Diseases (TRECARD), Department of Physiology and Pharmacology, University of Salamanca, Salamanca, Spain.|Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.
Ana I
AI
Morales
Translational Research on Renal and Cardiovascular Diseases (TRECARD), Department of Physiology and Pharmacology, University of Salamanca, Salamanca, Spain.|Institute of Health Sciences Studies of Castilla y Leon (IECSCYL), Research Unit, University Hospital of Salamanca, Spain.|Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.
Francisco J
FJ
López-Hernández
Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.|Renal and Cardiovascular Pathophysiology Unit, Institute Reina Sofia of Nephrological Research, Department of Physiology and Pharmacology, University of Salamanca, Salamanca, Spain.
José M
JM
López-Novoa
Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.|Molecular Medicine Unit, Department of Medicine, University of Salamanca and Institute of Molecular and Cellular Biology of Cancer (IBMCC), University of Salamanca-CSIC, Salamanca, Spain.
Rogelio
R
González-Sarmiento
Translational Research on Renal and Cardiovascular Diseases (TRECARD), Department of Physiology and Pharmacology, University of Salamanca, Salamanca, Spain.|Institute of Health Sciences Studies of Castilla y Leon (IECSCYL), Research Unit, University Hospital of Salamanca, Spain.|Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.
Carlos
C
Martínez-Salgado
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D055109:Ankle Brachial Index; D001786:Blood Glucose / Q000378:metabolism; D001794:Blood Pressure; D001835:Body Weight; D002318:Cardiovascular Diseases / Q000235:genetics* / Q000473:pathology; D016022:Case-Control Studies; D005260:Female; D006579:Heterozygote; D006801:Humans; D008297:Male; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide; D051567:Proto-Oncogene Proteins c-vav / Q000235:genetics*; D012161:Retinal Artery / Q000473:pathology; D012737:Sex Factors
D001786:Blood Glucose; D051567:Proto-Oncogene Proteins c-vav; C093651:VAV2 protein, human; C496621:VAV3 protein, human